BioSpace News Archive

Qualtrics, the leader in customer experience and creator of the experience management category, today announced that the American Heart Association, a nonprofit organization, has selected Qualtrics CoreXM.

BioAgilytix Labs is pleased to announce the appointment of Kennon Broadhurst to its Commercial Leadership team as Vice President of Global Marketing.

LUNGevity Foundation, the nation’s premier lung cancer-focused nonprofit organization, announced today that Maximilian Diehn, MD, PhD, has joined its Scientific Advisory Board.

At the onset of the pandemic the nation began to practice social distancing, and subsequently, many stopped scheduling visits with their doctors. Laboratories like Premier Medical Laboratory Services suddenly pivoted much of their efforts into providing a high volume of testing for COVID-19. Now, as more businesse

Humanigen, Inc., a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab™, announced that it has completed its previously announced underwritten public offering of common stock.

Bosma Enterprises and the Wounded Warrior Program are excited to announce a strategic partnership to generate opportunities and employment for people with vision loss and wounded veterans.

Precision Digital Health (PDH) today announced a strategic partnership enabling PDH to use Datavant’s data linking technology within their SUMMA platform.

Vynca, a national leader in advance care planning solutions, today announced a relationship with Cerner Corporation (Nasdaq: CERN), a global health care technology company, to help individuals and their families, caregivers and clinicians navigate the complex advance care planning process to ensure future care preferences are honored

-- First targeted antibody of its kind to be evaluated as a conditioning agent in patients with hematologic cancer undergoing stem cell transplantation, an area of significant unmet need -- -- Investigational humanized monoclonal antibody also being evaluated in a separate Phase 1 study as a conditioning agent in patients with severe combined immunodeficiency -- REDWOOD CITY, Calif.--( BUSINESS WIRE )-- Jasper Therapeutics, Inc., a biotechnol

TPG Capital, the private equity platform of alternative asset firm TPG, announced today that it has formed a new specialty pharmaceutical company called Ellodi Pharmaceuticals. Ellodi Pharmaceuticals is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare).